## Immunisation for adults requiring immunosuppressive disease modifying therapy 🗳 🗽 The Immunisation

**Advisory Centre** 

(excluding chemotherapy and stem cell transplant recipients - see specific factsheets)

For children aged under 18 years, please refer to the Starship Clinical Guideline Immunosuppression, infection and immunisation in rheumatology.

Vaccine	Additional notes	Recommended schedule	lmmunosuppression for longer than 28 days	
Immunisations should be delivered prior to elective immunosuppression if possible as response may be better and immunosuppression is a contraindication for some vaccines.				
Haemophilus influenzae type b Hib (Hiberix)		· Administer one dose	FUNDED	
Hepatitis B (Engerix-B)	If individual does not have a documented primary course of three hepatitis B vaccines	· Administer three doses at 0, 1 and 6 month intervals	FUNDED	
Human papilloma virus HPV (Gardasil 9)	· Males and females up to 45 years of age	· Administer three doses at 0, 2 and 6 month intervals	FUNDED up to 27 years of age	
Influenza	· Annually, during the funded Influenza Immunisation Programme	If prior to immunosuppression  · Administer one dose annually		
		If during immunosuppression  · Administer two doses four weeks apart in the first year of immunosuppression, only the first dose is funded.  · In subsequent years only one dose is required annually	FUNDED	
Meningococcal MenACWY (MenQuadfi)	No NeisVac-C (MenCCV) required     Prescription required for second primary dose	If prior to immunosuppression  · Administer one dose  · Schedule a precall for a booster dose every 5 years  If during immunosuppression  · Administer two doses 8 weeks apart  · Schedule a precall for a booster dose every 5 years	FUNDED for two doses	
Meningococcal B 4CMenB (Bexsero)	· Can be coadministered with any other vaccine	<ul> <li>Administer two doses 8 weeks apart</li> <li>Schedule a precall for a booster dose every 5 years<sup>f</sup></li> </ul>	FUNDED for two doses	
Pneumococcal PCV13 (Prevenar 13)	If Pneumovax 23 has been administered before Prevenar 13, wait one year to give Prevenar 13	· Administer one dose	Recommended NOT FUNDED	
Pneumococcal 23PPV (Pneumovax 23)	· Administer Pneumovax 23 a minimum of 8 weeks after Prevenar 13	If aged 18 years to under 60 years  Administer one dose  Schedule a precall for the second dose in 5 years  Schedule a precall for the third/final dose 5 years after second dose or at age 65 years, whichever is later  If aged 60 years or older  Administer one dose  Schedule a precall for the second/final dose in 5 years	Recommended NOT FUNDED	

## Immunisation for adults requiring immunosuppressive disease modifying therapy with The Immunisation

(excluding chemotherapy and stem cell transplant recipients - see specific factsheets)



Vaccine	Additional notes	Recommended schedule	Immunosuppression for longer than 28 days	
Immunisations should be delivered prior to elective immunosuppression if possible as response may be better and immunosuppression is a contraindication for some vaccines.				
SARS-CoV-2 (COVID-19)	<ul> <li>A third primary dose of mRNA-CV may be recommended depending on the type of immunosuppression</li> <li>Refer to Immunisation Handbook for specifics</li> </ul>	Administer vaccine doses following the recommended schedule for the available COVID-1 9vaccine	FUNDED	
Polio IPV (Ipol)	Check immunisation history for a primary course of three polio containing vaccines	If unsure of polio immunisation history  Administer three doses with a minimum of 4 weeks between each dose	FUNDED	
Tetanus/diphtheria/pertussis Tdap (Boostrix)	Check immunisation history for a primary course of three tetanus/diphtheria containing vaccines	If unsure of tetanus/diphtheria immunisation history  · Administer three doses with a minimum of 4 weeks between each dose  If has a confident recollection of completed tetanus/diphtheria immunisation  · Administer one Tdap atage 45 years if less than four documented tetanus containing vaccine doses  · Administer one Tdapat age 65 years	FUNDED	
Measles/mumps/rubella MMR (Priorix)	<ul> <li>Individuals born in 1969 or later who do not have two documented doses of MMR vaccine</li> <li>MMR vaccination is not required for adults born prior to 1969</li> </ul>	If less than two documented doses  · Complete a documented course of two MMR doses  · Administer up to two doses at least 4 weeks aparta,b,c,d	FUNDED for individuals who meet the eligibility criteria	
Varicella (chickenpox) VV (Varivax)	Individuals with no clinical history of varicella infection or vaccination	· Administer two doses at least 4 weeks aparta,b,c,d,e	CONTRAINDICATED From 4 weeks prior to immunosuppression	
Herpes zoster Recombinant ZV (Shingrix)	Recommended for:  · Adults from the age of 50 years and above  · Adults from the age of 18 years and above	· Administer 2 doses at least 2-6 months apart	Recommended NOT FUNDED 50-64 years	
	who are at increased risk of shingles  • Funded aged 65 years		FUNDED Aged 65 years	

## **Foot Notes**

- a. Individuals who have received immunoglobulin or other blood products may require time for passive antibodies to decrease prior to administration of live MMR and varicella vaccines. Refer to Table A6.1 in the current *Immunisation Handbook*. b. Two or more live vaccines can be given at the same visit. However, when live vaccines are administered at different visits, a minimum interval of 4 weeks is required.
- c. Live vaccines should not be given during the 4 weeks prior to elective immunosuppression.
- d. Consider normal immunoglobulin or zoster immunoglobulin for post-exposure measles or varicella prophylaxis respectively in immunosuppressed, non-immune individuals.
- e. Two doses of varicella vaccine are funded for a household contact of an individual who is severely immunocompromised or undergoing a procedure leading to immune compromise, where the household contact has no clinical history of varicella infection or immunisation.
- f. 4CmenB booster not currently funded for this group. Although the need for a booster dose after vaccination schedule has not been established, it is recommended and funded for other special groups. Refer to IHB Section 13.5.

